Durect Corporation Cash Flow Conversion Efficiency
Durect Corporation cash flow conversion efficiency. Based on the latest financial reports, Durect Corporation (DRRX) has a cash flow conversion efficiency ratio of -0.447x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($3.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Durect Corporation (1999–2024)
Cash flow conversion efficiency of Durect Corporation from 1999 to 2024. This chart illustrates how Durect Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Durect Corporation share price for real-time trading data and today's change.
Durect Corporation Cash Flow Conversion Ratio Explained
Durect Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Durect Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Durect Corporation ranked by their cash flow conversion efficiency. Also see Durect Corporation market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nebag ag
SW:NBEN
|
0.006x |
|
Oriental Food Industries Hold
KLSE:7107
|
0.047x |
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
-0.167x |
|
Ageagle Aerial Systems Inc
NYSE MKT:UAVS
|
-0.073x |
|
iLearningEngines, Inc.
NASDAQ:AILE
|
-3.216x |
|
Principal Real Estate Income Closed Fund
NYSE:PGZ
|
0.032x |
|
Comtrend Corp
TWO:8089
|
0.105x |
|
Newfield Resources Ltd
AU:NWF
|
0.201x |
Annual Cash Flow Conversion Efficiency for Durect Corporation (1999–2024)
The table below shows the annual cash flow conversion efficiency of Durect Corporation from 1999 to 2024. Review DRRX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.13 Million | $-19.09 Million | -2.090x | +10.21% |
| 2023-12-31 | $14.78 Million | $-34.41 Million | -2.328x | -121.32% |
| 2022-12-31 | $24.98 Million | $-26.28 Million | -1.052x | -62.89% |
| 2021-12-31 | $57.78 Million | $-37.31 Million | -0.646x | +33.07% |
| 2020-12-31 | $40.12 Million | $-38.70 Million | -0.965x | -298.68% |
| 2019-12-31 | $22.86 Million | $11.10 Million | 0.486x | +149.18% |
| 2018-12-31 | $20.00 Million | $-19.75 Million | -0.988x | -1480.00% |
| 2017-12-31 | $21.49 Million | $-1.34 Million | -0.063x | +98.09% |
| 2016-12-31 | $8.34 Million | $-27.29 Million | -3.273x | -137.01% |
| 2015-12-31 | $14.88 Million | $-20.55 Million | -1.381x | -79.96% |
| 2014-12-31 | $18.52 Million | $-14.21 Million | -0.767x | -52.62% |
| 2013-12-31 | $30.72 Million | $-15.45 Million | -0.503x | -35.85% |
| 2012-12-31 | $36.33 Million | $-13.45 Million | -0.370x | +92.60% |
| 2011-12-31 | $3.48 Million | $-17.39 Million | -5.000x | -1033.13% |
| 2010-12-31 | $14.49 Million | $7.76 Million | 0.536x | +170.31% |
| 2009-12-31 | $27.42 Million | $-20.89 Million | -0.762x | -194.20% |
| 2008-12-31 | $36.42 Million | $-9.43 Million | -0.259x | +51.04% |
| 2007-12-31 | $34.58 Million | $-18.30 Million | -0.529x | -106.69% |
| 2006-12-31 | $37.03 Million | $-9.48 Million | -0.256x | -53.89% |
| 2005-12-31 | $43.35 Million | $-7.21 Million | -0.166x | +86.23% |
| 2004-12-31 | $18.39 Million | $-22.21 Million | -1.208x | -183.08% |
| 2003-12-31 | $45.12 Million | $-19.25 Million | -0.427x | +9.82% |
| 2002-12-31 | $66.18 Million | $-31.31 Million | -0.473x | -104.69% |
| 2001-12-31 | $97.05 Million | $-22.43 Million | -0.231x | -78.92% |
| 2000-12-31 | $115.25 Million | $-14.89 Million | -0.129x | +63.18% |
| 1999-12-31 | $20.73 Million | $-7.27 Million | -0.351x | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more